Parmax Pharma
Parmax Pharma Share Price Chart
Parmax Pharma last traded at ₹137.75 (2026-10-13). Over the past month the stock moved +3.0%, three months the stock moved +263.5%, year the stock moved +318.4%. Its closing range over 52 weeks is ₹25.22 – ₹139.10, with the latest close 1.0% below the high.
Closing prices up to 2026-10-13.
About Parmax Pharma
Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals.[1]
Business Overview:[1] PPL is engaged in the manufacture and supply of bulk drugs (APIs) and selected formulations catering primarily to the Indian pharma industry.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Parmax Pharma reported sales of ₹8.22 crore (+323.7%) and net profit of ₹2.20 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 8.22 | 0.83 | 10.10 | 2.20 | 5.88 |
| Mar 2026 | 3.31 | -1.55 | -46.83 | -0.58 | -1.55 |
| Dec 2025 | 4.33 | -0.20 | -4.62 | -0.73 | -1.95 |
| Sep 2025 | 2.53 | -1.59 | -62.85 | -2.08 | -5.56 |
| Jun 2025 | 1.94 | -0.25 | -12.89 | -0.76 | -2.03 |
| Mar 2025 | 4.83 | -0.56 | -11.59 | -1.49 | -3.98 |
| Dec 2024 | 6.28 | 0.11 | 1.75 | -0.39 | -1.04 |
| Sep 2024 | 9.28 | 0.20 | 2.16 | -0.22 | -0.59 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +128.0% | +372.2% | +13.4% | -75.2% | -72.7% | -31.1% | -31.5% | +323.7% |
| Operating profit growth | – | – | – | -149.0% | -895.0% | -281.8% | – | – |
| Net profit growth | – | – | – | -7700.0% | – | – | – | – |
| EPS growth | – | – | – | -6866.7% | – | – | – | – |
| OPM % | 2.2% | 1.8% | -11.6% | -12.9% | -62.9% | -4.6% | -46.8% | 10.1% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Parmax Pharma reported sales of ₹12.11 crore (-57.1%) and net profit of ₹-4.16 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 12.11 | -3.64 | -30.06 | -4.16 | -11.12 |
| Mar 2025 | 28.20 | 0.26 | 0.92 | -2.09 | -5.59 |
| Mar 2024 | 11.02 | -3.37 | -30.58 | -5.78 | -15.45 |
| Mar 2023 | 15.39 | 2.25 | 14.62 | -0.10 | -0.27 |
| Mar 2022 | 18.24 | 2.57 | 14.09 | 0.14 | 0.37 |
| Mar 2021 | 26.17 | 3.43 | 13.11 | 0.75 | 2.00 |
| Mar 2020 | 20.92 | 1.77 | 8.46 | 0.43 | 1.15 |
| Mar 2019 | 11.99 | 1.11 | 9.26 | 0.08 | 0.21 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +0.8% | +74.5% | +25.1% | -30.3% | -15.6% | -28.4% | +155.9% | -57.1% |
| Operating profit growth | +2.8% | +59.5% | +93.8% | -25.1% | -12.5% | -249.8% | – | -1500.0% |
| Net profit growth | – | +437.5% | +74.4% | -81.3% | -171.4% | – | – | – |
| EPS growth | – | +447.6% | +73.9% | -81.5% | -173.0% | – | – | – |
| OPM % | 9.3% | 8.5% | 13.1% | 14.1% | 14.6% | -30.6% | 0.9% | -30.1% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Parmax Pharma.
Get Free AI Stock Analysis FREE →Latest News
-
Board of Parmax Pharma approves preferential issue of shares and warrants - Business Standard
-
Parmax Pharma approves preferential issue of shares and warrants - scanx.trade
-
Parmax Pharma Ltd Hits New 52-Week High of Rs.53.38 on 4 June 2026
-
When is the next results date for Parmax Pharma Ltd?
-
Parmax Pharma Re-appoints Dr. Umang Gosalia as Managing Director for Five Years - scanx.trade
-
Parmax Pharma Re-appoints Dr. Umang Gosalia as Managing Director for Five Years - scanx.trade
Frequently Asked Questions
What is Parmax Pharma's current stock price?
Parmax Pharma shares were last quoted at ₹137.75 (-1.0% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Parmax Pharma?
Parmax Pharma has a price-to-earnings (P/E) ratio of -43.18 and a price-to-book (P/B) ratio of 0.00. The industry P/E is 53.33.
What is the 52-week high and low of Parmax Pharma?
The 52-week high of Parmax Pharma is ₹137.75 and the 52-week low is ₹22.60.
What is the market cap of Parmax Pharma?
The market capitalisation of Parmax Pharma is about ₹51.54 crore.
How did Parmax Pharma perform in its latest quarterly results?
In the latest quarter (Jun 2026), Parmax Pharma reported sales of ₹8.22 crore (+323.7%) and net profit of ₹2.20 crore, compared with the same quarter last year.
What is the promoter holding in Parmax Pharma?
Promoters hold about 64.66% of Parmax Pharma.
Which sector does Parmax Pharma belong to?
Parmax Pharma belongs to the Pharmaceuticals & Drugs sector.